Xencor Inc. (NASDAQ:XNCR) received a $27.00 target price from Canaccord Genuity in a report released on Monday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price objective indicates a potential upside of 1.24% from the company’s current price.

XNCR has been the topic of several other reports. Piper Jaffray Cos. initiated coverage on Xencor in a research note on Tuesday, October 4th. They set an “overweight” rating and a $35.00 price objective on the stock. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research note on Tuesday, November 8th. Leerink Swann restated a “buy” rating and set a $26.00 price objective on shares of Xencor in a research note on Thursday, November 3rd. Wedbush restated an “outperform” rating and set a $27.00 price objective on shares of Xencor in a research note on Monday, September 12th. Finally, TheStreet cut Xencor from a “hold” rating to a “sell” rating in a research note on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.43.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Xencor (NASDAQ:XNCR) opened at 26.67 on Monday. Xencor has a 1-year low of $9.89 and a 1-year high of $26.77. The company has a 50 day moving average of $22.17 and a 200 day moving average of $18.95. The firm has a market capitalization of $1.10 billion, a P/E ratio of 27.33 and a beta of 2.20.

In related news, insider Edgardo Baracchini, Jr. sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $25.35, for a total value of $253,500.00. Following the sale, the insider now directly owns 10,000 shares in the company, valued at approximately $253,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III sold 40,000 shares of the business’s stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of $25.72, for a total value of $1,028,800.00. The disclosure for this sale can be found here. Insiders own 4.03% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Deerfield Management Co. boosted its stake in shares of Xencor by 175.9% in the first quarter. Deerfield Management Co. now owns 3,467,512 shares of the biopharmaceutical company’s stock worth $46,534,000 after buying an additional 2,210,900 shares in the last quarter. Nationwide Fund Advisors raised its position in Xencor by 5.0% in the second quarter. Nationwide Fund Advisors now owns 54,822 shares of the biopharmaceutical company’s stock worth $1,041,000 after buying an additional 2,615 shares during the last quarter. Acrospire Investment Management LLC raised its position in Xencor by 8.5% in the second quarter. Acrospire Investment Management LLC now owns 6,347 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 495 shares during the last quarter. Bank of New York Mellon Corp raised its position in Xencor by 5.5% in the second quarter. Bank of New York Mellon Corp now owns 132,627 shares of the biopharmaceutical company’s stock worth $2,519,000 after buying an additional 6,965 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Xencor by 11.9% in the second quarter. California State Teachers Retirement System now owns 67,434 shares of the biopharmaceutical company’s stock worth $1,281,000 after buying an additional 7,167 shares during the last quarter. Institutional investors and hedge funds own 69.70% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

5 Day Chart for NASDAQ:XNCR

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.